COVID-19 (Coronavirus) Update

February 27, 2020

AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus.” As an active participant in the pharmaceutical supply chain, we’re engaged with health officials and are constantly communicating with manufacturers, monitoring inventory levels and customer purchasing behavior for any potential impact to the supply chain. We will continue to be highly engaged as the situation evolves on a day-to-day basis.

As of February 27, 2020, we have not received any formal notifications from supply chain partners regarding drug shortages in light of the Coronavirus. FDA spokeswoman Stephanie Caccomo shared that the FDA has been in contact with manufacturers regarding 20 drugs, not specifically identified, at risk of shortage due to the outbreak. The agency contacted manufacturers of these drugs, and none reported an expected shortage due to the outbreak.

According to the FDA as of February 27, “the U.S. Government considers this a serious public health concern, based on current information, the immediate health risk from COVID-19 to the general American public is considered low at this time.”

We will continue to update our customers as needed as the situation evolves. With questions, please contact your AmerisourceBergen representative.